Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, with a poor prognosis and limited therapeutic options. Due to its overexpression in the majority of HCCs, alpha-fetoprotein (AFP) represents one of the most useful markers for hepatocarcinomas and for monitoring patients' response to therapy. Although it was earlier reported that AFP has immunosuppressive properties, it has been recently demonstrated that AFP induces spontaneous T and B cells responses in HCC patients. The characterization of AFP-immunogenic epitopes gives the opportunity to design AFP-based cancer vaccines for human HCC. The activity of AFP-based vaccines has been investigated in HCC mouse models in order to develop novel strategies to treat patients with HCC. This review will discuss the rationale for using the AFP-based vaccination strategy and recent results corroborating the usefulness of AFP vaccines as a potential tool for cancer therapy
Keywords: Alpha fetoprotein, cancer vaccine, immune response, peptide, tumor marker, oncofetal protein, phenylbutazone, streptomycin, anilinonaphthaline sulfate, immunoregulatory agent, immunosuppression, immune dysfunction, apoptosis, neovascularization, neoplastic growth
Current Molecular Medicine
Title: Alpha Fetoprotein is More than a Hepatocellular Cancer Biomarker: From Spontaneous Immune Response in Cancer Patients to the Development of an AFP-Based Cancer Vaccine
Volume: 11 Issue: 7
Author(s): R. Bei and G.J. Mizejewski
Affiliation:
Keywords: Alpha fetoprotein, cancer vaccine, immune response, peptide, tumor marker, oncofetal protein, phenylbutazone, streptomycin, anilinonaphthaline sulfate, immunoregulatory agent, immunosuppression, immune dysfunction, apoptosis, neovascularization, neoplastic growth
Abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, with a poor prognosis and limited therapeutic options. Due to its overexpression in the majority of HCCs, alpha-fetoprotein (AFP) represents one of the most useful markers for hepatocarcinomas and for monitoring patients' response to therapy. Although it was earlier reported that AFP has immunosuppressive properties, it has been recently demonstrated that AFP induces spontaneous T and B cells responses in HCC patients. The characterization of AFP-immunogenic epitopes gives the opportunity to design AFP-based cancer vaccines for human HCC. The activity of AFP-based vaccines has been investigated in HCC mouse models in order to develop novel strategies to treat patients with HCC. This review will discuss the rationale for using the AFP-based vaccination strategy and recent results corroborating the usefulness of AFP vaccines as a potential tool for cancer therapy
Export Options
About this article
Cite this article as:
Bei R. and Mizejewski G.J., Alpha Fetoprotein is More than a Hepatocellular Cancer Biomarker: From Spontaneous Immune Response in Cancer Patients to the Development of an AFP-Based Cancer Vaccine, Current Molecular Medicine 2011; 11 (7) . https://dx.doi.org/10.2174/156652411800615162
DOI https://dx.doi.org/10.2174/156652411800615162 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design DSPE-PEG: A Distinctive Component in Drug Delivery System
Current Pharmaceutical Design Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Synthesis, Cytotoxicity and Docking Simulation of Novel Annulated Dihydroisoquinoline Heterocycles
Mini-Reviews in Medicinal Chemistry Monoclonal Antibody “Gold Rush”
Current Medicinal Chemistry New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Targeting miRNAs for Pancreatic Cancer Therapy
Current Pharmaceutical Design Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Recent Progress in the Identification and Clinical Evaluation of Inhibitors of the Mitotic Kinesin KSP
Current Topics in Medicinal Chemistry COX-2 and Colorectal Cancer
Current Pharmaceutical Design Edging Toward Personalized Medicine
Current Pharmacogenomics Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers
Current Cancer Drug Targets PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Recent Patents Involving Virus Nucleotide Sequences; Host Defense, RNA Silencing and Expression Vector Strategies
Recent Patents on DNA & Gene Sequences Antibody-directed Double Suicide Gene Therapy Targeting of MUC1- Positive Leukemia Cells In Vitro and In Vivo
Current Gene Therapy Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design